GREENWICH LIFESCIENCES, INC. Accounts Payable and Accrued Liabilities
GREENWICH LIFESCIENCES, INC. (GLSI) had Accounts Payable and Accrued Liabilities of $220.84 thousand as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Liabilities › Accounts Payable and Accrued Liabilities
us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent · last filed 2026-08-11
- 2026-06-30: Accounts Payable and Accrued Liabilities $220.84K.
- 2026-03-31: Accounts Payable and Accrued Liabilities $220.84K.
- 2025-12-31: Accounts Payable and Accrued Liabilities $220.84K.
- 2025-09-30: Accounts Payable and Accrued Liabilities $220.84K.
| Period end | Accounts Payable and Accrued Liabilities |
|---|---|
| 2026-06-30 | $220.84K 10-Q · filed 2026-08-11 |
| 2026-03-31 | $220.84K 10-Q · filed 2026-06-04 |
| 2025-12-31 | $220.84K 10-Q · filed 2026-08-11 |
| 2025-09-30 | $220.84K 10-Q · filed 2025-11-14 |
| 2025-06-30 | $220.84K 10-Q · filed 2025-08-14 |
| 2025-03-31 | $220.84K 10-Q · filed 2025-05-20 |
| 2024-12-31 | $220.84K 10-K · filed 2026-06-01 |
| 2023-12-31 | $220.84K 10-K · filed 2025-04-15 |
| 2023-09-30 | $220.84K 10-Q · filed 2023-10-19 |
| 2023-06-30 | $220.84K 10-Q · filed 2023-08-21 |
| 2022-12-31 | $220.84K 10-K · filed 2024-04-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |